#USA #FDA Approval #Datar Cancer Genetics #Nashik #CellDx-Tissue

Datar Cancer Genetics Achieves Landmark FDA Approval for CellDx-Tissue

Datar Cancer Genetics (DCG), a leader in precision oncology, has proudly announced that its innovative tissue-based testing solution, CellDx-Tissue, has been granted approval by the U.S. Food and Drug Administration (FDA). This significant development provides a comprehensive genomic profiling option for solid tumors, utilizing both DNA and RNA analysis.

What is CellDx-Tissue?

CellDx-Tissue stands as a cutting-edge in vitro diagnostic assay that employs targeted Next-Generation Sequencing (NGS). This technology dissects the genetic material extracted from formalin-fixed, paraffin-embedded (FFPE) tumor tissues. With a focus on 517 oncological genes, the assay delivers critical information pertaining to somatic single nucleotide variants (SNVs), minor insertions and deletions (InDels), and gene amplifications, especially targeting significant fusions involving ALK, RET, and ROS1 genes. Conducted at a CAP and CLIA-accredited laboratory, the test ensures precision and reliability, thereby empowering oncologists worldwide in making well-informed therapeutic decisions in accordance with established international guidelines.

Impact on Precision Oncology

The importance of comprehensive genomic profiling cannot be overstated in today’s cancer landscape. It serves as a foundational component in modern diagnostics and treatment planning by accurately characterizing genomic alterations across various types of cancer. Achieving FDA approval, recognized globally for its stringent evaluation process, underscores the robustness of DCG’s technology and positions the company as a pivotal player in the field of precision oncology.

Dr. Vineet Datta, Senior Director of Global Strategy and Business Development at DCG, emphasized, “The FDA approval for CellDx-Tissue represents a crucial regulatory recognition for a central solution within our company. It bridges complex genomic data with clinical decision-making, offering patients expanded treatment options in a constantly evolving therapeutic landscape.”

Scientific Rigor and Standards

DCG prides itself on its commitment to scientific excellence and high standards throughout its development and quality assurance systems. Dr. Darshana Patil, Senior Director of Group Medical Affairs, reiterated that the FDA's endorsement validates the scientific integrity of their genomic panel. It provides healthcare professionals with standardized genomic information that is essential for navigating complex treatment pathways in cancer therapy.

Dr. Dadasaheb Akolkar, Director of Research and Innovation, added, “This approval reflects the persistent scientific efforts and clinical orientation with which our teams have advanced the development of CellDx-Tissue. We look forward to making our innovative precision oncology solutions accessible to an even broader array of patients globally.”

Datar Cancer Genetics: Pioneering the Future of Cancer Diagnostics

Datar Cancer Genetics is not just a company; it is a forward-thinking entity that leverages artificial intelligence to enhance precision oncology solutions. Their portfolio encompasses advanced cancer diagnostics, including non-invasive liquid biopsy techniques and tissue-based multi-omics analyses designed for early detection, treatment selection, and monitoring of cancer.

With accredited laboratories (UKAS, CAP, CLIA) and operational structures in countries such as the United Kingdom, the European Union, the United States, the United Arab Emirates, and across Asia, DCG collaborates globally with medical facilities and oncologists to deliver personalized care to patients afflicted with solid tumors.

For further information, visit Datar Cancer Genetics.